Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Acumen Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Acumen Pharmaceuticals, Inc.’s stock price such as:

• Acumen Pharmaceuticals, Inc.’s current stock price and volume
• Why Acumen Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ABOS from analysts
• ABOS’s stock price momentum as measured by its relative strength

About Acumen Pharmaceuticals, Inc. (ABOS)

Before we jump into Acumen Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Want to learn more about Acumen Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Acumen Pharmaceuticals, Inc..

Acumen Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 15, 2026, 4:00 PM, CST, Acumen Pharmaceuticals, Inc.’s stock price was $2.280.

Acumen Pharmaceuticals, Inc. is down 4.6% from its previous closing price of $2.390.

During the last market session, Acumen Pharmaceuticals, Inc.’s stock traded between $2.260 and $2.400. Currently, there are approximately 63.22 million shares outstanding for Acumen Pharmaceuticals, Inc..

Acumen Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Acumen Pharmaceuticals, Inc. Stock Price History

Acumen Pharmaceuticals, Inc.’s (ABOS) price is currently down 4.6% so far this month.

During the month of May, Acumen Pharmaceuticals, Inc.’s stock price has reached a high of $2.740 and a low of $2.260.

Over the last year, Acumen Pharmaceuticals, Inc. has hit prices as high as $3.600 and as low as $0.990. Year to date, Acumen Pharmaceuticals, Inc.’s stock is up 8.06%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Acumen Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 15, 2026, there was 1 analyst who downgraded Acumen Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Acumen Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Acumen Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Acumen Pharmaceuticals, Inc. (ABOS) by visiting AAII Stock Evaluator.

Relative Price Strength of Acumen Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 15, 2026, Acumen Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 11.25%, which translates to a Momentum Score of 83 and is considered to be Very Strong.

Want to learn more about how Acumen Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Acumen Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 15, 2026, Acumen Pharmaceuticals, Inc.’s stock price is $2.280, which is down 4.6% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Acumen Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.